Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 8/20 | 0.33 |
| ▸ | AKT2 | P31751 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073526 | 0.81 | FGFR1 (0.42) | HASPINFGFR1AKT1AKT2ALDH1A1 | |
| SCHEMBL6073354 | 0.80 | MEN1 (0.38) | HASPINAKT1AKT2ALDH1A1CYP1A2 | |
| SCHEMBL29742257 | 0.80 | FGFR1 (0.40) | HASPINFGFR1AKT1AKT2MEN1 | |
| SCHEMBL6073344 | 0.80 | FGFR1 (0.40) | HASPINFGFR1AKT1AKT2MEN1 | |
| SCHEMBL3293161 | 0.80 | MEN1 (0.41) | HASPINFGFR1AKT1AKT2ALDH1A1 | |
| SCHEMBL30837298 | 0.80 | HASPIN (0.36) | HASPINFGFR1AKT1AKT2 | |
| SCHEMBL2039264 | 0.78 | MEN1 (0.41) | HASPINALDH1A1CYP1A2GAACYP2C9 | |
| SCHEMBL14014291 | 0.76 | MAPK8 (0.45) | — | |
| SCHEMBL20943032 | 0.74 | FGFR1 (0.41) | FGFR1AKT1AKT2ALDH1A1CYP2C19 | |
| SCHEMBL15269745 | 0.72 | BRAF (0.42) | HASPINFGFR1AKT1AKT2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1254137-A1 | PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055147-A1 | PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | HASPIN 3207/4885FGFR1 280/4885AKT1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.